INTRODUCTION
============

Bone homeostasis is mediated by the balanced regulation of bone-forming osteoblasts and bone-resorbing osteoclasts ([@b1-molcell-37-11-827]). Osteoclasts are derived from hematopoietic progenitors of the monocyte/macrophage lineage and the binding of receptor activator of nuclear factor-κB (NF-κB) ligand (RANKL) to its receptor, RANK, on osteoclast precursors induces osteoclast differentiation ([@b18-molcell-37-11-827]; [@b28-molcell-37-11-827]). The elevation of bone resorption by osteoclasts causes a variety of bone diseases such as osteoporosis, Paget's disease, rheumatoid arthritis, and periodontitis ([@b1-molcell-37-11-827]; [@b11-molcell-37-11-827]; [@b12-molcell-37-11-827]; [@b27-molcell-37-11-827]).

Differentiation of osteoclasts is accompanied by changes in the expression levels of various genes ([@b1-molcell-37-11-827]; [@b12-molcell-37-11-827]; [@b27-molcell-37-11-827]). Several techniques including differential display-PCR ([@b8-molcell-37-11-827]; [@b10-molcell-37-11-827]), subtractive hybridization ([@b15-molcell-37-11-827]; [@b24-molcell-37-11-827]), and cDNA microarrays ([@b14-molcell-37-11-827]; [@b32-molcell-37-11-827]) have been employed to investigate differentially-expressed genes during differentiation of osteoblasts or osteoclasts. The development of cDNA microarrays allowed the screening of quantitative differences of thousands of genes. While most studies have focused on either osteoblasts or molecular change in response to RANKL ([@b14-molcell-37-11-827]; [@b32-molcell-37-11-827]), total analyses of gene expression in response to insulin stimulation in osteoclasts have little been studied.

Insulin is an important regulator not only of glucose metabolism by increasing cellular glucose uptake but also of bone metabolism. Insulin receptors are expressed in many cell types including osteoblasts, chondrocytes, and osteoclasts and the activation of insulin receptor by insulin stimulation induces its downstream mediators, thus regulating cellular metabolism, growth, survival, and differentiation ([@b6-molcell-37-11-827]; [@b7-molcell-37-11-827]; [@b17-molcell-37-11-827]; [@b29-molcell-37-11-827]; [@b33-molcell-37-11-827]). Recently, we have shown that insulin promoted osteoclast proliferation through up-regulation of cyclinD1 and Bcl2A1 ([@b17-molcell-37-11-827]). Studies using osteoblast-specific insulin receptor-deficient mice have demonstrated that insulin receptor signaling in osteoblasts affects not only osteoblast proliferation but also energy metabolism ([@b6-molcell-37-11-827]; [@b7-molcell-37-11-827]). Moreover, patients with diabetes mellitus exhibit altered bone metabolism with resultant changes in bone mineral density (BMD) ([@b13-molcell-37-11-827]; [@b30-molcell-37-11-827]). Thus, insulin is one of main factors mediating the crosstalk between bone remodeling and energy metabolism.

Here, we investigated the genes that were differentially-expressed by insulin on osteoclast precursors using cDNA microarray. The identification of these genes provided the first systematic information on the response of the osteoclast precursors to insulin at the level of gene transcription. It could be useful in identifying biochemical markers for the diagnosis of numerous bone and metabolic diseases, or as potential targets for the development of therapeutic agents.

MATERIALS AND METHODS
=====================

Isolation of bone marrow precursors and cell culture
----------------------------------------------------

Isolation of bone marrow precursors was performed as described previously ([@b3-molcell-37-11-827]). Briefly, bone marrow cells were flushed out from the femur of 4--6-week-old C57BL/6 mice with a sterile 21-gauge syringe and incubated in alpha-MEM media containing 10% FBS and 10 ng/ml M-CSF (R&D Systems). After 24 h, non-adherent cells were harvested and cultured in the presence of M-CSF (20 ng/ml) for 3 days. After washing out the non-adherent cells, adherent cells were used as bone marrow-derived monocytes/macrophages (BMMs). Culture media was changed every 2 days.

RNA preparation
---------------

Total RNA was extracted using Trizol (Invitrogen Life Technologies, USA) and then purified using RNeasy columns (Qiagen, USA) according to the manufacturer's protocol. For quality control, the RNA purity and integrity were evaluated by denaturing gel electrophoresis, measuring the absorbance at 260 and 280 nm, and analyzed on Agilent 2100 Bioanalyzer (Agilent Technologies, USA).

Microarray experiments
----------------------

Total RNA was amplified and purified using an Ambion Illumina RNA amplification kit (Ambion, USA) to yield biotinylated cRNA according to the manufacturer's instructions. Briefly, 550 ng of total RNA were reverse- transcribed to cDNA using a T7 oligo (dT) primer. Second- strand cDNA was synthesized, transcribed *in vitro*, and labeled with biotin-NTP. After purification, the cRNA was quantified using a ND-1000 spectrophotometer (NanoDrop, USA). A total of 750 ng of labeled cRNA samples were hybridized to each mouse-8 expression bead array for 16--18 h at 58°C, according to the manufacturer's instructions (Illumina, Inc., USA). Detection of an array signal was conducted using Amersham fluorolink streptavidin-Cy3 (GE Healthcare Bio-Sciences, UK) following the bead array manual. Arrays were scanned with an Illumina bead array reader confocal scanner according to the manufacturer's instructions. The quality of hybridization and overall chip performance were monitored by visual inspection of both internal quality control checks and the raw scanned data. Raw data were extracted by the software provided by the manufacturer \[Illumina GenomeStudio v2009.2 (Gene Expression Module v1.5.4)\]. Probe signal value was transformed by logarithm and normalized by the quantile method. The comparative analysis between the test and control groups was carried out using fold-change, LPE test adjusted FDR p value. False discovery rate (FDR) was controlled by adjusting the p value using the Benjamini-Hochberg algorithm. Go-ontology analysis for the list of significant probes was performed using PANTHER (<http://www.pantherdb.org/panther/ontologies.jsp>), using text files containing Gene ID list and the accession number of illumina probe ID.

cDNA synthesis and real-time PCR
--------------------------------

Total RNA isolated from cells treated with RANKL (Peprotech) or insulin (Sigma) was used as a template for cDNA synthesis. The reverse transcription of total RNA to cDNA was performed with Superscript III reverse transcriptase (Invitrogen) according to the manufacturer's protocol. Real-time PCRs were performed with the Brilliant UltraFast SYBR Green QPCR Master Mix (Agilent Technologies) and specific primers for target genes and HPRT (for endogenous control) from QIAGEN in triplicates on an MX3000 instrument (Agilent Technologies). HPRT was used for normalization of all quantitation.

Statistical analysis
--------------------

Data were expressed as mean ± S.D. from at least 3 independent experiments. Statistical differences were analyzed by student's *t*-test. *P* \< 0.05 was considered statistically significant.

RESULTS AND DISCUSSION
======================

Analysis of microarray expression data
--------------------------------------

We isolated BMMs from mice femur and then treated the cells with 10 nM of insulin for 6 h, 12 h or 24 h in the presence of MCSF, to explore genes regulated by insulin in osteoclast precursors. Stimulation with insulin for 6 h resulted in significant up-regulation of 76 genes and down-regulation of 96 genes; and for 12 h, up-regulation of 73 genes and down-regulation of 83 genes. Insulin treatment for 24 h caused up-regulation of 39 genes and down-regulation of 54 genes compared to the non-treated cells ([Fig. 1](#f1-molcell-37-11-827){ref-type="fig"}). These data suggested that stimulation with insulin induced a change of immediate-early genes rather than late genes in osteoclast precursors. Furthermore, the results indicated that insulin signaling in osteoclasts may be associated with cellular and molecular events of proliferation or differentiation in osteoclasts.

Gene expression profiles in insulin-treated cells
-------------------------------------------------

Up- or down-regulated genes in response to insulin treatment were classified according to the Panther group analysis based on 20 biological processes or 24 molecular functions (<http://www.pantherdb.org>) as presented in [Figs. 2A and 2B](#f2-molcell-37-11-827){ref-type="fig"}, respectively. Among the groups classified by biological processes, the biggest was 'signal transduction', *i.e.* 109 genes, in which cytokines such as interleukin-15 (IL-15) and chemokine (C-X-C motif) ligand 10 were included (data not shown). The next was 'immunity- and defense', *i.e.* 69 genes. 25 genes were found to be associated with 'developmental processes' and 18 genes with 'cell proliferation and differentiation'. The number of 'receptor'- and 'signaling molecules'-included genes based on 24 molecular functions, were 35 and 31 respectively. This result revealed that insulin induced changes in expression of genes involved in various cellular and molecular events in osteoclasts.

Most of these genes are involved in 'housekeeping' activities of many cell types. We focused on the 'developmental processes'- and 'cell proliferation and differentiation'-related genes since the identification of these genes can help to elucidating the molecular mechanism that underlies bone remodeling and energy metabolism. The lists of 'developmental processes'- and 'cell proliferation and differentiation'-related genes were presented in [Tables 1](#t1-molcell-37-11-827){ref-type="table"} and [2](#t2-molcell-37-11-827){ref-type="table"}, respectively. As shown in [Table 1](#t1-molcell-37-11-827){ref-type="table"}, Inhba, Socs, Mllt11, Clec2d, Dscr1, Tnc, Plk3, and Egr2 were up-regulated in the insulin-treated groups. Conversely, Emb, Tlr8, Tlr13, Ednrb, Vim, Itm2b, Fabp5, Plk1, Tgfbr2, Ang, and Fgd2 were down-regulated. In the 'cell proliferation and differentiation' group, IL1a, Cxcl10, Sphk1, Il1b, Cdkn1a, Plk3, Inhba, Ccnd1, Cd86, and Pdgfb were up-regulated whereas Tnfsf4, Ednrb, Uhrf1, and Plk1 were down-regulated ([Table 2](#t2-molcell-37-11-827){ref-type="table"}).

Validation of microarray results and comparison with the effects of RANKL
-------------------------------------------------------------------------

Real-time PCR was performed to verify the gene expression profiles provided by the microarray analysis. Microarray results were confirmed by real-time PCR and, overall, real-time PCR results were found to be very similar to the microarray results, as shown in [Fig. 3](#f3-molcell-37-11-827){ref-type="fig"}: insulin induced mRNA expression of Socs2, Plk3, Il1a, Cxcl10, Il1b, and Inhba, while it repressed the expression of Plk1 and Tnfsf4 in osteoclast precursors. These results corroborated microarray as an efficient technique to identify a large number of differentially expressed genes.

Changes in the genes expression were examined after RANKL treatment for 12 h and 24 h, to study the comparative effects of insulin and RANKL in osteoclast precursors. Most of the genes, except Tnfsf4 and Inhba, showed very similar expression patterns between insulin- and RANKL-treated cells. Among these genes, Socs2 was increased in response to both insulin and RANKL in osteoclast precursors. Suppressor of cytokine signaling 2 (SOCS2) is a suppressor of the Janus kinase (JAK) and signal transducers and activators of transcription (STAT) signal transduction pathway ([@b16-molcell-37-11-827]; [@b20-molcell-37-11-827]). The role of SOCS2 seems to be controversial since Socs2^−/−^ mice displayed an increased longitudinal skeletal growth associated with a deregulated GH/IGF-I signaling ([@b21-molcell-37-11-827]) whereas it resulted in reduced trabecular and cortical volumetric BMD ([@b20-molcell-37-11-827]). The cellular role of SOCS2 by insulin and RANKL remains to be investigated further. Polo-like kinases (PLKs) consist of a family of kinases which play critical roles during multiple stages of cell cycle progression ([@b25-molcell-37-11-827]; [@b26-molcell-37-11-827]; [@b31-molcell-37-11-827]). Whereas Plk1 has been linked to cell proliferation, several studies have observed that Plk3 expression was negatively correlated with cancer development ([@b4-molcell-37-11-827]; [@b5-molcell-37-11-827]; [@b26-molcell-37-11-827]). In the present study, we found that whereas Plk3 was up-regulated, Plk1 was down-regulated by insulin and RANKL treatment, which implied that insulin and RANKL may contribute to osteoclast differentiation by regulating proliferation through diametrically opposed control on PLK1 and PLK3.

Interestingly, Tnfsf4 and Inhba genes were differentially affected by insulin and RANKL: both were not changed by RANKL but notably decreased or increased by insulin, respectively. OX40L, a member of the TNF family, encoded by Tnfsf4 gene ([@b22-molcell-37-11-827]), played a role as a late checkpoint in diabetes development ([@b23-molcell-37-11-827]). The targeting of OX40L reduced the incidence of diabetes ([@b23-molcell-37-11-827]) but promoted osteoclastogenesis ([@b9-molcell-37-11-827]). Activins betaA (encoded by Inhba) is a member of the TGF-beta superfamily. Inhba-deficient mice were small and lean because of reduced IGF-1 levels, the abnormalities of growth plates, and the increased mitochondrial energy metabolism ([@b2-molcell-37-11-827]; [@b19-molcell-37-11-827]). Based on these earlier observations, our results implied that OX40L and activin may be involved in osteoclast insulin receptor signaling, rather than RANKL, and thus specifically on osteoclasts or islet biology.

Taken together, these results implied that insulin could play not only similar roles on osteoclast precursors as RANKL, or enhance the effects of RANKL, but also have unique independent roles. Although, the direct role of insulin on osteoclast differentiation or RANKL signaling and the examination to molecular pathways involving these genes are still the subjects of further research, this study gives hints for the development of therapeutic agents for bone and metabolic diseases.
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![The number of genes changed by insulin treatment. The number of genes changed by ≥ 1.5 fold in cells treated with 10 nM of insulin for 6 h, 12 h or 24 h compared to un-treated controls, were determined after microarray.](molcell-37-11-827f1){#f1-molcell-37-11-827}

![Analyses of genes changed by insulin treatment. The genes were analyzed by grouping according to biological process (A) or molecular function (B) and counted.](molcell-37-11-827f2){#f2-molcell-37-11-827}

![Validation of microarray results and comparison with the effects of RANKL. Relative expression of each gene induced by 10 nM of insulin or 200 nM of RANKL for the indicated times by real-time PCR. \**P* \< 0.05 *vs*. cells without stimulation, \#*P* \< 0.05 *vs*. cells treated with insulin.](molcell-37-11-827f3){#f3-molcell-37-11-827}

###### 

List of "developmental processes"-related genes regulated by insulin treatment in primary osteoclast precursors

  Gene symbol   Description                                   6 h (fold)   12 h (fold)   24 h (fold)
  ------------- --------------------------------------------- ------------ ------------- -------------
  Emb           Embigin                                       −1.52        −1.34         −1.38
  Tlr8          Toll-like receptor 8                          −1.58        −1.39         −1.30
  Tlr13         Toll-like receptor 13                         −1.58        −1.43         −1.32
  Inhba         Inhibin beta-A                                1.78         1.54          1.36
  Socs2         Suppressor of cytokine signaling 2            1.59         1.54          1.26
  Mllt11        Mixed-lineage leukemia; translocated to,11    1.58         1.51          1.34
  Clec2d        C-type lectin domain family 2, member d       1.43         1.54          1.39
  Ednrb         Endothelin receptor type B                    −1.46        −1.53         −1.65
  Vim           Vimentin                                      −1.17        −1.27         −1.53
  Itm2b         Integral membrane protein 2B                  −1.50        −1.32         −1.26
  Fabp5         Fatty acid binding protein 5                  −1.61        −1.44         −1.24
  Dscr1         Down syndrome critical region gene 1          1.97         2.06          2.11
  Tnc           Tenascin C                                    1.56         1.71          1.71
  Plk1          Polo-like kinase 1 (Drosophila)               −1.66        −1.70         −1.42
  Plk3          Polo-like kinase 3 (Drosophila)               1.89         1.82          1.40
  Tgfbr2        Transforming growth factor, beta receptor 2   −1.81        −1.63         −1.36
  Egr2          Early growth response 2                       1.74         1.70          1.22
  Ang           Angiogenin                                    −1.69        −1.59         −1.40
  Fgd2          FYVE, RhoGEF and PH domain containing 2       −1.80        −1.56         −1.37

###### 

List of "cell proliferation & differentiation"-related genes regulated by insulin treatment in primary osteoclast precursors

  Gene symbol   Description                                                 6 h (fold)   12 h (fold)   24 h (fold)
  ------------- ----------------------------------------------------------- ------------ ------------- -------------
  Tnfsf4        Tumor necrosis factor superfamily, member 4                 −1.41        −1.55         −1.56
  Ednrb         Endothelin receptor type B                                  −1.46        −1.53         −1.65
  Uhrf1         Ubiquitin-like, containing PHD and RING finger domains, 1   −1.63        −1.55         −1.33
  Plk1          Polo-like kinase 1 (Drosophila)                             −1.66        −1.70         −1.42
  Il1a          Interleukin1 alpha                                          2.93         2.48          1.72
  Cxcl10        Chemokine (C-X-C motif) ligand 10                           2.29         1.96          1.71
  Sphk1         Sphingosine kinase 1                                        1.99         1.96          1.73
  Il1b          Interleukin1 beta                                           1.71         1.78          1.51
  Cdkn1a        Cyclin-dependent kinase inhibitor 1A                        1.65         1.54          1.62
  Plk3          Polo-like kinase 3 (Drosophila)                             1.89         1.82          1.40
  Inhba         Inhibin beta-A                                              1.78         1.54          1.36
  Ccnd1         CyclinD1                                                    1.60         1.56          1.41
  Cd86          CD86 antigen                                                1.59         1.63          1.41
  Pdgfb         Platelet-derived growth factor beta polypeptide             1.48         1.54          1.39
